EGFR and neoplasm: The mechanism by which the combination of antiangiogenic drugs and EGFR-TKIs provides benefits may stem from the ability of antiangiogenic agents to normalize blood flow in tumor blood vessels, thereby enhancing drug delivery and concentration within tumors [64, 65].